MFC
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
MFC makes the active pharmaceutical ingredients (APIs), the chemically synthesized compounds that give a medicine its therapeutic effect, used in treatments for cardiovascular disease, chronic bronchitis, diabetes, and musculoskeletal conditions, among others.
It supplies these ingredients, along with the key starting materials and intermediate compounds needed to produce them, to pharmaceutical manufacturers. Listed on KOSDAQ, Korea's tech and small-cap board, the company covers both established generic-drug ingredients and early-stage novel or improved-drug materials, giving it two distinct business lines within a single chemistry-focused operation.
Summary is AI-generated and may contain errors · figures from DART filings
Its APIs are manufactured to meet the pharmacopoeia standards of Korea, the United States, Europe, and Japan, enabling supply to multiple regulated markets.
MFC in five facts
What does MFC do?
MFC makes the active pharmaceutical ingredients (APIs), the chemically synthesized compounds that give a medicine its therapeutic effect, used in treatments for cardiovascular disease, chronic bronchitis, diabetes, and musculoskeletal conditions, among others.
Where is MFC listed and in which sector?
MFC (Korean name: 엠에프씨) trades under KRX code 432980 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is MFC?
Its market capitalisation was US$15.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were MFC's latest annual revenue and operating profit?
For fiscal year 2025, MFC reported revenue of US$15.7M, operating profit of US$223.9K and net income of US$620.3K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 0.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Treasury share acquisition: results report
MFC Co., Ltd. reported completing, between June 16 and July 31, 2026, the on-exchange purchase of 334,579 treasury common shares (average price US$2.03) for a total of US$703K, essentially matching its planned US$703K budget; its total treasury holding is now 850,249 shares, 3.9% of outstanding shares.
Treasury Shares · Aug 6 - Material event report (treasury share acquisition)
MFC disclosed a plan to buy back its own shares worth US$661K, about 4.5% of its market value.
Treasury Shares · Jun 15 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
MFC reported separate results for FY2025: revenue of US$14.4M (+0.9% year on year), operating profit of US$206K (−79.7% year on year) and net income of US$549K (from a loss a year earlier).
Earnings · Feb 13 - Treasury share disposal: results reportTreasury Shares · Jan 5